Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by pembrolizumab treatment.

Trial Details

NCT ID
NCT04991948
Phase
PHASE1
Sponsor
Celyad Oncology SA
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • CYAD-101
  • FOLFOX
  • Pembrolizumab
Locations (sample)
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Tampa, Florida, United States|27.94752,-82.45843
  • Edegem, Belgium|51.15662,4.44504
  • Ghent, Belgium|51.05,3.71667
  • Leuven, Belgium|50.87959,4.70093

Key Eligibility Criteria

  • Histologically proven metastatic adenocarcinoma of the colon or rectum.
  • Confirmed metastatic unresectable adenocarcinoma of the colon or the rectum.
  • Confirmed non-microsatellite instability high (non-MSI-H)/mismatch-repair proficient (pMMR) tumor status
  • Unequivocal and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →